You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update

ID: GL-1-A-2016-2 oct 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Catherine Van Poznak, Mark R. Somerfield, William E. Barlow, J. Sybil Biermann, Linda D. Bosserman, Mark J. Clemons, Sukhbinder K. Dhesy-Thind, Melissa S. Dillmon, Andrea Eisen, Elizabeth S. Frank, Reshma Jagsi, Rachel Jimenez, Richard L. Theriault, Theodore A. Vandenberg, Gary C. Yee, Beverly Moy, ASCO-CCO Update Committee

Guideline Objective

To update, in collaboration with Cancer Care Ontario (CCO), key recommendations of the American Society of Clinical Oncology (ASCO) guideline on the Role of Bone-Modifying Agents (BMA) in Metastatic Breast Cancer. This focused update addressed the new data on intervals between dosing and the role of bone-modifying agents in control of bone pain.

Patient Population

Patients with bone metastases from breast cancer

Intended Guideline Users

Medical oncologists, radiation oncologists, surgical oncologists, oncology nurses, advanced practice providers, patients, patient advocates, caregivers, and oncology pharmacists

Research Questions

  • What are the best intervals between dosing of zoledronic acid?
  • What is the role of bone-modifying agents in control of pain secondary to bone metastases?